Researcher
Chris Verslype
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From22 May 2017 → Today - Hepatology (Division)
Member
From1 Oct 2002 → 21 May 2017
Projects
1 - 10 of 14
- Impact of ccfDNA on clinical decision making in NEN patientsFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPTFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- [18F]AlF-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors: comparison with [68Ga]Ga-DOTATATE and evaluation of routine clinical use.From3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- robotiC gUided canceR nanomedicinE (CURE)From1 Oct 2021 → TodayFunding: BOF - projects
- New Strategies in Locoregional, Minimally Invasive Therapy of Liver CancerFrom1 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → 1 Oct 2023Funding: FWO Strategic Basic Research Grant
- Methylome analysis in circulating tumor DNA to predict baseline or aquired sorafenib resistance in hepatocellular carcinoma patientsFrom1 Jan 2019 → 31 Dec 2022Funding: Foundations, funds and other with scientific goal
- Daphnia: from ecological to biomedical microbiome model in the context of hypoxiaFrom1 Sep 2018 → 26 Jun 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- The role of cytopathology in the management of patients with pancreatic tumours - special focus on neuroendocrine tumoursFrom15 Jun 2017 → 17 Sep 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- Pancreatic cancer: study of tumor biology and EMT with testing of corresponding drugs in a relevant pre-clinical modelFrom1 Oct 2016 → 30 Sep 2018Funding: BOF - Other initiatives
Publications
1 - 10 of 304
- Spatiotemporal Analysis of Particle Spread to Assess the Hybrid Particle-Flow CFD Model of Radioembolization of HCC Tumors.(2024)
Authors: Chris Verslype, Geert Maleux
Pages: 1219 - 1227 - Mendez-Blanco et al. Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells (vol 15, 1984, 2019)(2023)
Authors: Jos van Pelt, Chris Verslype
- Genotype specific and microbiome effects of hypoxia in the model organism Daphnia magna(2023)
Authors: Manon Coone, Karen Bisschop, Chris Verslype, Ellen Decaestecker
Pages: 1669 - 1683 - PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma(2023)
Authors: Sarah Cappuyns, Bram Boeckx, Ingrid Arijs, Aurelie Mechels, Baki Topal, Chris Verslype, Diether Lambrechts, Jeroen Dekervel
- Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients(2023)
Authors: Vincent Vandecaveye, Chris Verslype
- Hepatitis B virus (HBV)-related outcomes in patients (pts) with baseline HBV infection in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)(2023)
Authors: Chris Verslype
Pages: S218 - S218 - The ongoing search for biomarkers of response to systemic therapy in advanced hepatocellular carcinoma.(2023)
Authors: Sarah Cappuyns, Jeroen Dekervel, Eric Van Cutsem, Chris Verslype, Diether Lambrechts
- Rituximab and improved nodular regenerative hyperplasia-associated non-cirrhotic liver disease in common variable immunodeficiency: a case report and literature study(2023)
Authors: Willem Roosens, Stephanie Humblet-Baron, Isabelle Meyts, Chris Verslype, Hannah van Malenstein, Schalk Van der Merwe, Wim Laleman, Rik Schrijvers
- Robotic Versus Laparoscopic Hepatectomy: A Single Surgeon Experience of 629 Consecutive Minimally Invasive Liver Resections(2023)
Authors: Chris Verslype
Pages: 2241 - 2249 - Impact on clinical management when using [18F]AlFNOTA-octreotide instead of [68Ga]Ga-DOTA-SSA PET/CT in neuroendocrine tumor patients: preliminary results(2023)
Authors: Jeroen Dekervel, Frederik Cleeren, Michel Koole, Guy Bormans, Chris Verslype, Christophe Deroose
Pages: S508 - S508